Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy

Clinical Lung Cancer

Volumn 5, Issue 5, 2004, Pages 274-289

  Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Carboplatin; Cisplatin; Elderly patients; Paclitaxel; Performance status

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ETOPOSIDE; FOLIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN G1 ANTIBODY; MESNA; MITOMYCIN; NAVELBINE; PACLITAXEL; PACLITAXEL DERIVATIVE; PEMETREXED; PLATINUM DERIVATIVE; TEGAFUR; UNINDEXED DRUG; URACIL; VINBLASTINE; VINDESINE;

ACNE; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; EARLY CANCER; ELDERLY CARE; ESOPHAGUS DISEASE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALAISE; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PREOPERATIVE TREATMENT; PSYCHOPATHY; RADIATION DOSE; REVIEW; THROMBOCYTOPENIA;

EID: 2442418050     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.007     Document Type: Review

References (90)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-1100.
3. Stephens RJ, Fairlamb N, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21:291a (Abstract #1161).
4. Delbaldo C, Syz N, Michiels S, et al. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature. Proc Am Soc Clin Oncol 2003; 22:623 (Abstract #2507).
5. Baggstrom MQ, Socinski MA, Hensing TA, et al. Addressing the optimal number of cytotoxic agents in stage IIIA/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2003; 22:624 (Abstract #2510).
6. Lilenbaum RC, Herndon J, List M, et al. Single-agen (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21:1a (Abstract #2).
7. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer: a phase III study by the Swedish Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 2002; 21:291a (Abstract #1162).
8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353.
9. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20:3578-3585.
10. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357:1478-1484.
11. Satouchi M, Takada Y, Takeda K, et al. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc Am Soc Clin Oncol 2001; 20:329a (Abstract #1312).
12. Takeda K, et al, Yamamoto N, Negoro S, et al. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC): a West Japan Thoracic Oncology Group (WJTOG) study. Proc Am Soc Clin Oncol 2000; 79:497a (Abstract #1944).
13. Smit EF, van Meerbeeck JPAM, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21:3909-3917.
14. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum, sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21:3207-3213.
15. Treat J, Belani CP, Edelman M, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB,IV) non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:624 (Abstract #2511).
16. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025-3034.
17. Schiller JH. Platin or no platin? That is the question. J Clin Oncol 2003; 21:3009-3010.
18. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409-422.
19. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-3024.
20. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8:1556-1562.
21. Novakova L, Novakova L, Petruzelka L, et al. Gemcitabine plus cisplatin (Gcis) versus gemcitabine plus carboplatin (Gcarb) in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:307a (Abstract #1225).
22. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13:1539-1549.
23. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 2002; 13:1515-1517.
24. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
25. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
26. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
27. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
28. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
29. Kubota K, Watanabe K, Kunitoh H, et al. Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:296a (Abstract #1180).
30. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71:366-370.
31. Larsen H, Sorensen JB, Nielsen AL, et al. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC). Ann Oncol 1995; 6:993-997.
32. Smith IE, O'Brien MER, Talbot DC, et al. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19:1336-1343.
33. Andresen D, Behrens S, Stern R, et al. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the noninvasive approach. J Cardiovasc Pharmacol 1992; 20(suppl 2):S28-S31.
34. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335-1343.
35. DePierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small-cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (pts) responding to induction therapy (French Cooperative Oncology Group). Proc Am Soc Clin Oncol 2001; 20:309a (Abstract #1231).
36. Socinski MA, Schell MJ, Bakri K, et al. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer 2002; 95:1265-1273.
37. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21:2933-2939.
38. Socinski MA, Baggstrom MQ, Hensing TA, et al. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol 2003; 1:33-38.
39. Hanna N, Paul S, DeMarinis F, et al. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41(suppl 2):55-56.
40. Hanna NH, Shepherd FA, Rosell R, et al. A phase III study of pemetrexed vs. docetaxel in patients wtih recurrent non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 2003; 22:622 (Abstract #2503).
41. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
42. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
43. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
44. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:2529-2536.
45. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372.
46. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94:173-181.
47. Kelly K, Giarritta S, Akerley W, et al. Should older patients receive combination chemotherapy for advanced non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc Am Soc Clin Oncol 2001; 21:320a (Abstract #1313).
48. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV non-small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003; 98:779-788.
49. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (> 70). Proc Am Soc Clin Oncol 2003; 22:639 (Abstract #2571).
50. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36:453-471.
51. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92:2639-2647.
52. Ukena D, Schroeder M, Dittrich I, et al. Phase III randomised trial comparing paclitaxel/carboplatin (PC) every 3 weeks with weekly paclitaxel/carboplatin in patients (pts) with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:623 (Abstract #2506).
53. Socinski MA, Hensing TA, Escudero M, et al. Randomized phase II trial of weekly carboplatin/paclitaxel (C/P) versus every-3-week C/P in advanced non-small cell lung cancer (NSCLC): a pure schedule trial. Lung Cancer 2003; 41:155.
54. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
55. Herbst RS, Giaccone G, Schiller GH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
56. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced EGFR-expressing non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:310a (Abstract #1235).
57. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small-cell lung cancer: Final report. Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2581).
58. Kelly K, Hanna N, Rosenberg A, et al. A multi-center phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:644 (Abstract #2592).
59. Robert F, Blumenschein G, Dicke K, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:643 (Abstract #2587).
60. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2582).
61. Clark GM, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 2003; 33:196 (Abstract #786).
62. Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 2002; 7(suppl 4):9-15.
63. Reif MS, Socinski MA, Rivera MP. Evidence-based medicine in the treatment of non-small-cell lung cancer. Clin Chest Med 2000; 21:107-120.
64. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 85:673-678.
65. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153-158.
66. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1-6.
67. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7-14.
68. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247-253.
69. Depierre A, Westeel V, Milleron B, et al. 5-Year results of the French randomized study comparing preoperative chemotherapy followed by surgery and primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. Lung Cancer 2003; 41(suppl 2):S2.
70. Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RT)G 93-09). Proc Am Soc Clin Oncol 2003; 22:621 (Abstract #2497).
71. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
72. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma. A randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991; 20:1183-1190.
73. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699.
74. Curran WJ, Jr., Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000; 19:484a (Abstract #1891).
75. Pierre F, Maurice R, Gilles R, et al. A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study). Proc Am Soc Clin Oncol 2001; 21:312a (Abstract #1246).
76. Zatloukal PV, Petruzelka L, Zemanova M, et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 2002; 21:290a (Abstract #1159).
77. Bonomi P, Curran WJ, Choy H, et al. Randomized phase II study of three chemoradiation regimens with paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41(suppl 2):77.
78. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.
79. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001; 92:1213-1223.
80. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352:257-263.
81. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology (Huntingt) 2003; 17:357-364.
82. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899-909.
83. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343:1217-1222.
84. Scagliotti GV, Fossati R, Torri V, et al for the Adjuvant Lung Project Italy/European Organisation for Research and Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
85. Alam SQ, Alam BS. Effect of essential fatty acid deficiency and high fat diet on fatty acid composition of rat gingiva. J Periodont Res 1980; 15:633-637.
86. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360.
87. Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119:429-439.
88. Bunn PA, Pisters KMW, Vallieres E, et al. Southwest Oncology Group S9900: a randomized phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin in clinical stage IB (T2N0), II (T-12N1, T3N0) and selected IIIA (T3N1) non-small cell lung cancer. Available at: www.swog.org.visitors/viewprotocolDetails.asp?protocolID=52; Accessed March 29, 2004.
89. Hodson A, for the Medical Research Council. Surgery with or without preoperatve chemotherapy in treating patients with resectable non-small cell lung cancer (protocol). Available at: www.clinicaltrials.gov/ct/show/NCT00003159?order=27. Accessed: January 14, 2004.
90. Depierre A, for the French Thoracic Onocology Group (IFCT). Randomized clinical trial comparing two preoperative chemotherapy regimens in stage I and II non-small cell lung cancer (NSCLC) (protocol IFCT 0002). Available at: www.ifct.asso.fr/protocole01-english.htm. Accessed March 29, 2004.